

VARIANT IDENTIFICATION AND INTERPRETATION FROM NEXT GENERATION SEQUENCING

Bioinformatics Unit Seminar Series
Tuesday, May 28th

Seth I. Berger, MD, PhD

Assistant Professor

Center for Genetic Medicine Research, Children's National Medical Center

Rare Disease Institute, Division of Genetics and Metabolism, Children's National Medical Center

Department of Genomics and Precision Medicine; and of Pediatrics, GWU SMHS

Objectives

- Overview of Next Generation Sequencing
- Variant Identification Tools and Pipeline
- Variant Interpretation

Next Generation Sequencing


- **Next-generation sequencing** refers to non-Sanger-based high-throughput DNA sequencing technologies.
- Millions or billions of DNA strands can be sequenced in parallel
- More throughput and minimizing the need for the fragment-cloning methods that are often used in Sanger sequencing of genomes

Sequencing


Purpose: Sequence bases identification

4 Steps:

- ✓ Library preparation
- ✓ Cluster generation
- ✓ Sequencing
- ✓ Data analysis



Bioinformatic Workflow



Definitions

- Reads: inferred sequence of base pairs corresponding to a part or a whole DNA
- Raw data: Formatted Sequence of DNA/RNA/AA
- Paired ends: Forward and reverse read of same cluster
- Pipeline: structured execution commands

Files description


FastA format

- Header
- Sequence

```
>GXP_210035 loc=GXL_175098|sym=FAM149A|taxid=9606|spec=Homo  
sapiens|chr=4|ctg=NC_000004|str=(+)|start=187065495|end=187066181|len=687|  
Region  
GGACGGGCGTGGAAAGGGTCCACGTCTTTAGTATGCATGCTTAGATCTAGCGTTCCCTGTTGATGGAGTAATGGT!  
TTGACCAGATCCGGGGCTTCATTTTTTAAACCTCATTGTCCTACTCCCCACCCAGCCTGGTGTGCGCACCCCT!  
GGCGGGGATAGGCGAGATGGTCTGTGGTTCCTCTGCCCTTCTCTGGTGAATTTAAAATCCGATTTGGAAGAGAG!  
GCCAGCACCAAGTATGCACAGCCCCCGCCCCAGAGACCCGGGAAGGAGTAGGGAGGCCGGGCCGTGCGCGGAGC  
CGCTGGGTTGGAAACCCGGCCCGGCAGGGAGCGGGGAAGGCGCGCTTCCCGGAGGTCGGCGCGGGGCCGGGGC  
CGGGGCCCGGAGCGGGGATGGGCGGGCGCAGCCGGGATTTAGCTGGCGGGCGAGGGCGCAGCGCAGGGAGGAGG!  
GCGGCGCCGGCGCGGGCGGGGCGGAGGATCTGGAGAGGGAAGGGGCGTGCAGCCCCGCGGACCCCGGGCGCGC  
CGCCTGAGCTGGGCCAGCCGCGCGGGCCCGGGCGCGGGCGCGGGCGGGCGGGGCGGGTGGGGAGCCCC  
GGGGCCCGGGGGCGCGTGACCGGCTGTCTGCGTGGGGCCCGCGCGC
```

FastQ format

- Header
- Quality score
- Sequence




Alignment

Burrows-Wheeler Aligner (BWA)

Map low-divergent sequences against a large reference genome.

- ✓ SOLiD
- ✓ Illumina
- ✓ IonTorrent
- ✓ Sanger
- ✓ Assembly contigs
- ✓ PacBio
- ✓ BACSeq
- ✓ 454




Files description

Sequence Alignment Map format (SAM)

- Alignment
- Quality Scores
- Read
- Sample information
- Data compression
 - BAM
 - CRAM

HEADER containing metadata (sequence dictionary, read group definitions etc)
RECORDS containing structured read information (1 line per read record)




```
@HD VN:1.0 S0:coordinate
@SQ SN:chr20 LN:64444167
@PG ID:TopHat VN:2.0.14 CL:/srv/dna_tools/tophat/tophat -N 3 --read-edit-dist 5 --read-rea
lign-edit-dist 2 -i 50 -I 5000 --max-coverage-intron 5000 -M -o out /data/user446/mapping_tophat/index/chr
20 /data/user446/mapping_tophat/L6_18_GTGAAA_L007_R1_001.fastq
HWI-ST1145:74:C101DACXX:7:1102:4284:73714 16 chr20 190930 3 100M * 0 0
CCGTGTTAAAGGTGGATGCGGTACCTTCCCAGCTAGGGCTTAGGGATTCTTACTGGCTAGGAAATCCAGCTAGTCTCTCAGTCCCCCTCT
C BDDCCDDCCDDDDDDDDDDCCCCBC?DDDDDDDDDDDDDDCCDDDDDDDDCCCCEDDDC?DDDDDDDDDDDDDDDDDDDDDDHFFFDDC@
AS:i:-15 XM:i:3 XO:i:0 XG:i:0 MD:Z:55C20C13A9 NM:i:3 NH:i:2 CC:Z:= CP:i:55352714 HI:i:0
HWI-ST1145:74:C101DACXX:7:1114:2759:41961 16 chr20 193953 50 100M * 0 0
TGCTGGATCATCTGTTAGTGGCTTCTGACTCAGAGGACCTTCTGCCCCGGGGCAGTGGACCTTCCAGTATTCCCCTGACATAAGGGGCATGGACGA
G DCDDDDDDDDDDDDDDDDDDCCDDDDDDDDDEEC>DFFFEJJJJJJIGJJJJIHGBHHGJIIJJJJGJJJJIIHJJJJHHHHHHFFFFCC
AS:i:-16 XM:i:3 XO:i:0 XG:i:0 MD:Z:60G16T18T3 NM:i:3 NH:i:1
HWI-ST1145:74:C101DACXX:7:1204:14760:4030 16 chr20 270877 50 100M * 0 0
GGCTTTATTGGTAAGAAAGGAATGACAGATTTAATCAGAAATCCCACCTGGCCAGCAGCACCAACCAGAAGAAGGAAGAAGACAGGAAAAACCA
C DDDDDDDDDDDDDDDDEEEEEEEFFFEFFEGHHHHFGDJJIIHJJIIJJJJIIIGGFJJIHIIIIJJJJJIGHHFAHGFIHJFGHHFFDD@BB
AS:i:-11 XM:i:2 XO:i:0 XG:i:0 MD:Z:0A85G13 NM:i:2 NH:i:1
HWI-ST1145:74:C101DACXX:7:1210:11167:8699 0 chr20 271218 50 50M4700N50M * 0
0 GTGGCTCTCCACAGGAATGTTGAGGATGACATCCATGTCTGGGTGCACCTGGGTCTCCGAAGCAGAACATCCTCAAATATGACCTCTCG
accepted_hits.sam
```

Variant Pileups


Viewed in IGV

Example heterozygous and homozygous 3 base pair deletion



Variant Calling

- Statistically call variants from aligned sequences
- GATK Haplotype Caller, Platypus, etc
- Calls SNVs and Indels



Other Types of Variant Calling

- Most clinical pipelines are optimized for germline variants
- Other specific variant callers can be integrated into pipeline

- Copy Number Variants
 - Depth of coverage (XHMM, etc)
 - Aberrant Mate Pair Insertion size (Mseq)
- Translocation
 - Aberrant Mate pair distribution (Breakdancer, etc)
- Mosaic Variants
 - LoFreq, Mutect2, etc

File format description: Summary

Formats	Input for	Output from
FastA	BLAST Multiple Sequence Alignment (MSA) Database query tools	Older Sequencers Sequence Database store Converters
FastQ	FasQC Aligners Assemblers Variants detection/SNP callers	Sequencers (default format) Format Converters
SAM/BAM/CRAM	Alignment algorithms Some Assemblers Alignment viewers Variants detection	Aligners Assemblers
VCF	VCF tools SNP Annotation	SNP caller Haplotyping Software Variant Information Database
BED/BEDGrap	Alignment viewers Bed tools Some annotation	Features detection

Files description

Variant Calling Format (VCF)

- Shows variants, not genetic features.
- Can have additional per variant and per sample annotations

```
##fileformat=VCFv4.2
##fileDate=20151002
##source=callMomV0.2
##reference=gi|251831106|ref|NC_012920.1| Homo sapiens mitochondrion, complete genome
##contig=<ID=MT,length=16569,assembly=b37>
##INFO=<ID=VT,Number=.,Type=String,Description="Alternate allele type. S=SNP, M=MNP, I=Indel">
##INFO=<ID=AC,Number=.,Type=Integer,Description="Alternate allele counts, comma delimited when multiple">
##FILTER=<ID=fa,Description="Genotypes called from fasta file">
##FORMAT=<ID=GT,Number=1,Type=String,Description="Genotype">
#CHROM POS ID REF ALT QUAL FILTER INFO FORMAT HG00096 HG00097 HG00099
MT 10 . T C 100 fa VT=S;AC=3 GT 0 0 0
MT 16 . A T 100 fa VT=S;AC=3 GT 0 0 0
MT 26 . C T 100 fa VT=S;AC=3 GT 0 0 0
MT 35 . G A 100 fa VT=S;AC=2 GT 0 0 0
MT 40 . TC CT 100 fa VT=M;AC=1 GT 0 0 0
```

Annotation

ANNOtate VARiants (ANNOVAR)

- ✓ Program for functional annotation.
- ✓ Can identify Structure variants and examine functional consequences on gene.
- ✓ Disease identification.
- ✓ All species.

SNP Effect (SNPEff)

- ✓ Program for annotating and predicting the effects of SNP.
- ✓ Annotate thousands variants/sec.
- ✓ Based on the genomic position.
- ✓ Many species.

Objectives

- Overview of Next Generation Sequencing
- Variant Identification Tools and Pipeline
- Variant Interpretation

Clinical Variant Interpretation

- Clinical versus Research Variant Interpretation
- Cautions about variant interpretation
- ACMG Reportable Secondary Finding Genes
- ACMG Variant Classification Guidelines

Clinical vs Research Variant Interpretation

- Research Variant Interpretation

- Association of variants to Phenotype
 - Note: GWAS variants are not necessarily disease causing, typically linked to a truly pathogenic variant
- Functional effects of variants
- Molecular function, pathways, structure, localization, etc...

- Clinical Variant Interpretation


- Does this variant cause a phenotype?
- Does this variant change what the doctor does clinically?
- Is more testing needed for this patient or does variant provide an answer?
- Can family make reproductive decisions based on variant?

Cautions about variant interpretation


- Proving a variant causes functional changes in a protein does not mean it is clinically relevant.
 - Models may not always be able to recapitulate a phenotype.
 - Example: MTHFR: 1298A>C
 - Originally studied as possible contribution to thrombosis
 - Functional studies showed variants with somewhat decreases/altered activity
 - Multiple conflicting studies linking to many different things from autism to cancer.
 - Found to be very very common in population at large
 - Some families refusing vaccination based on this or spending money on expensive supplements without known clinical benefit...

MTHFR Common Polymorphism Frequencies at CNMC

A. Allele Frequencies



B. Genotype Frequencies



What variants get reported clinically?

- Varies from lab to lab
- Depends on test ordered:
 - Targeted gene tests/panel
 - Untargeted tests (exomes, genomes)
 - Prenatal / Postnatal
 - Screening vs. Testing
- Carrier status?
- Secondary findings?

ACMG Reportable Secondary Findings

- ACMG curated list of genes where pathogenic variants in a healthy individual would change medical management
 - Cancer susceptibility genes with early screening options
 - Cardiac arrhythmia genes with medication options/possible defibrillators
 - Serious potential drugs side effects where medication choices may prevent life threatening effects
 - Treatable inborn errors of metabolism with late onset
- Only Pathogenic / Likely Pathogenic variants returnable
- May not report uncertain variants
- Recommends people be offered option of receiving these results even if these are not included on indication for sequencing.
- Some research studies will offer return of these results.

How Clinicians Talk about Variants

- Pathogenic → Most likely causes a disease
 - Describes variant (not genotype)
- Likely Pathogenic → Probably related to the disease, but can't be certain
 - In right clinical setting, can be considered the answer
- Variant of uncertain significance → Not enough evidence to judge
 - Challenging discussions and clinical reasoning
- Likely Benign → No reason to believe it causes a disease, but can't be sure
- Benign → Too Common to cause disease

ACMG Variant Classification Guidelines

© American College of Medical Genetics and Genomics

ACMG STANDARDS AND GUIDELINES

**Genetics
inMedicine**

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

Sue Richards, PhD¹, Nazneen Aziz, PhD^{2,16}, Sherri Bale, PhD³, David Bick, MD⁴, Soma Das, PhD⁵, Julie Gastier-Foster, PhD^{6,7,8}, Wayne W. Grody, MD, PhD^{9,10,11}, Madhuri Hegde, PhD¹², Elaine Lyon, PhD¹³, Elaine Spector, PhD¹⁴, Karl Voelkerding, MD¹³ and Heidi L. Rehm, PhD¹⁵; on behalf of the ACMG Laboratory Quality Assurance Committee

Criteria Overview

	Benign			Pathogenic		
	Strong	Supporting	Supporting	Moderate	Strong	Very strong
Population data	MAF is too high for disorder BA1/BS1 OR observation in controls Inconsistent with disease penetrance BS2			Absent in population databases PM2	Prevalence in affecteds statistically increased over controls PS4	
Computational and predictive data		Multiple lines of computational evidence suggest no impact on gene /gene product BP4 Missense in gene where only truncating cause disease BP1 Silent variant with non predicted splice impact BP7 In-frame indels in repeat w/out known function BP3	Multiple lines of computational evidence support a deleterious effect on the gene /gene product PP3	Novel missense change at an amino acid residue where a different pathogenic missense change has been seen before PM5 Protein length changing variant PM4	Same amino acid change as an established pathogenic variant PS1	Predicted null variant in a gene where LOF is a known mechanism of disease PVS1
Functional data	Well-established functional studies show no deleterious effect BS3		Missense in gene with low rate of benign missense variants and path. missenses common PP2	Mutational hot spot or well-studied functional domain without benign variation PM1	Well-established functional studies show a deleterious effect PS3	
Segregation data	Nons segregation with disease BS4		Cosegregation with disease in multiple affected family members PP1	Increased segregation data →		
De novo data				De novo (without paternity & maternity confirmed) PM6	De novo (paternity and maternity confirmed) PS2	
Allelic data		Observed in <i>trans</i> with a dominant variant BP2 Observed in <i>cis</i> with a pathogenic variant BP2		For recessive disorders, detected in <i>trans</i> with a pathogenic variant PM3		
Other database		Reputable source w/out shared data – benign BP6	Reputable source – pathogenic PP5			
Other data		Found in case with an alternate cause BP5	Patient's phenotype or FH highly specific for gene PP4			

Very Strong Criteria

Evidence of pathogenicity

Category

Very strong

PVS1 null variant (nonsense, frameshift, canonical ± 1 or 2 splice sites, initiation codon, single or multiexon deletion) in a gene where LOF is a known mechanism of disease

Caveats:

- Beware of genes where LOF is not a known disease mechanism (e.g., *GFAP*, *MYH7*)
- Use caution interpreting LOF variants at the extreme 3' end of a gene
- Use caution with splice variants that are predicted to lead to exon skipping but leave the remainder of the protein intact
- Use caution in the presence of multiple transcripts

Note the caveats

- **Loss of function must be a known mechanism**
- Variants that escape nonsense mediated decay
 - Certain disease genes for example WHIM syndrome and FAM83H Amelogenesis imperfecta, truncation mutations lead to gain of function effect which are pathogenic while loss of function mutations are tolerable (at least in a heterozygous state)
- In-frame exon skipping
- Minor Transcripts

Strong Criteria

Strong

PS1 Same amino acid change as a previously established pathogenic variant regardless of nucleotide change

Example: Val→Leu caused by either G>C or G>T in the same codon

Caveat: Beware of changes that impact splicing rather than at the amino acid/protein level

PS2 De novo (both maternity and paternity confirmed) in a patient with the disease and no family history

Note: Confirmation of paternity only is insufficient. Egg donation, surrogate motherhood, errors in embryo transfer, and so on, can contribute to nonmaternity.

PS3 Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product

Note: Functional studies that have been validated and shown to be reproducible and robust in a clinical diagnostic laboratory setting are considered the most well established.

PS4 The prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls

Note 1: Relative risk or OR, as obtained from case-control studies, is >5.0, and the confidence interval around the estimate of relative risk or OR does not include 1.0. See the article for detailed guidance.

Note 2: In instances of very rare variants where case-control studies may not reach statistical significance, the prior observation of the variant in multiple unrelated patients with the same phenotype, and its absence in controls, may be used as moderate level of evidence.

Moderate Criteria

Moderate

PM1 Located in a mutational hot spot and/or critical and well-established functional domain (e.g., active site of an enzyme) without benign variation

PM2 Absent from controls (or at extremely low frequency if recessive) (**Table 6**) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium

Caveat: Population data for insertions/deletions may be poorly called by next-generation sequencing.

PM3 For recessive disorders, detected in *trans* with a pathogenic variant

Note: This requires testing of parents (or offspring) to determine phase.

PM4 Protein length changes as a result of in-frame deletions/insertions in a nonrepeat region or stop-loss variants

PM5 Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before

Example: Arg156His is pathogenic; now you observe Arg156Cys

Caveat: Beware of changes that impact splicing rather than at the amino acid/protein level.

PM6 Assumed de novo, but without confirmation of paternity and maternity

Supporting Criteria

Supporting

PP1 Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease

Note: May be used as stronger evidence with increasing segregation data

PP2 Missense variant in a gene that has a low rate of benign missense variation and in which missense variants are a common mechanism of disease

PP3 Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.)

Caveat: Because many in silico algorithms use the same or very similar input for their predictions, each algorithm should not be counted as an independent criterion. PP3 can be used only once in any evaluation of a variant.

PP4 Patient's phenotype or family history is highly specific for a disease with a single genetic etiology

PP5 Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation

Benign Criteria

Evidence of benign impact	Category
Stand-alone	BA1 Allele frequency is >5% in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium
Strong	<p>BS1 Allele frequency is greater than expected for disorder (see Table 6)</p> <p>BS2 Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age</p> <p>BS3 Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing</p> <p>BS4 Lack of segregation in affected members of a family</p> <p>Caveat: The presence of phenocopies for common phenotypes (i.e., cancer, epilepsy) can mimic lack of segregation among affected individuals. Also, families may have more than one pathogenic variant contributing to an autosomal dominant disorder, further confounding an apparent lack of segregation.</p>
Supporting	<p>BP1 Missense variant in a gene for which primarily truncating variants are known to cause disease</p> <p>BP2 Observed in <i>trans</i> with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in <i>cis</i> with a pathogenic variant in any inheritance pattern</p> <p>BP3 In-frame deletions/insertions in a repetitive region without a known function</p> <p>BP4 Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc.)</p> <p>Caveat: Because many in silico algorithms use the same or very similar input for their predictions, each algorithm cannot be counted as an independent criterion. BP4 can be used only once in any evaluation of a variant.</p> <p>BP5 Variant found in a case with an alternate molecular basis for disease</p> <p>BP6 Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation</p> <p>BP7 A synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice site AND the nucleotide is not highly conserved</p>

Combining Criteria

Table 5 Rules for combining criteria to classify sequence variants

Pathogenic	<ul style="list-style-type: none"> (i) 1 Very strong (PVS1) <i>AND</i> <ul style="list-style-type: none"> (a) ≥ 1 Strong (PS1–PS4) <i>OR</i> (b) ≥ 2 Moderate (PM1–PM6) <i>OR</i> (c) 1 Moderate (PM1–PM6) and 1 supporting (PP1–PP5) <i>OR</i> (d) ≥ 2 Supporting (PP1–PP5) (ii) ≥ 2 Strong (PS1–PS4) <i>OR</i> (iii) 1 Strong (PS1–PS4) <i>AND</i> <ul style="list-style-type: none"> (a) ≥ 3 Moderate (PM1–PM6) <i>OR</i> (b) 2 Moderate (PM1–PM6) <i>AND</i> ≥ 2 Supporting (PP1–PP5) <i>OR</i> (c) 1 Moderate (PM1–PM6) <i>AND</i> ≥ 4 supporting (PP1–PP5) 	Likely pathogenic	<ul style="list-style-type: none"> (i) 1 Very strong (PVS1) <i>AND</i> 1 moderate (PM1–PM6) <i>OR</i> (ii) 1 Strong (PS1–PS4) <i>AND</i> 1–2 moderate (PM1–PM6) <i>OR</i> (iii) 1 Strong (PS1–PS4) <i>AND</i> ≥ 2 supporting (PP1–PP5) <i>OR</i> (iv) ≥ 3 Moderate (PM1–PM6) <i>OR</i> (v) 2 Moderate (PM1–PM6) <i>AND</i> ≥ 2 supporting (PP1–PP5) <i>OR</i> (vi) 1 Moderate (PM1–PM6) <i>AND</i> ≥ 4 supporting (PP1–PP5)
		Benign	<ul style="list-style-type: none"> (i) 1 Stand-alone (BA1) <i>OR</i> (ii) ≥ 2 Strong (BS1–BS4)
		Likely benign	<ul style="list-style-type: none"> (i) 1 Strong (BS1–BS4) and 1 supporting (BP1–BP7) <i>OR</i> (ii) ≥ 2 Supporting (BP1–BP7)
		Uncertain significance	<ul style="list-style-type: none"> (i) Other criteria shown above are not met <i>OR</i> (ii) the criteria for benign and pathogenic are contradictory

Source of Information

- Annovar / VEP / SnpEff/ etc
 - Variant annotations (Computational predictors, population frequencies)
 - SIFT, Polyphen, CADD, etc...
 - Splice prediction
- Exac / Gnomad
 - Population Frequencies
- Varsome, etc
 - Variant annotations in web interface
- UCSC genome browser
- Uniprot
- Clinvar
 - Previously classified variants

Mutation and Variant Databases

Table 1 Population, disease-specific, and sequence databases

Population databases	
Exome Aggregation Consortium http://exac.broadinstitute.org/	Database of variants found during exome sequencing of 61,486 unrelated individuals sequenced as part of various disease-specific and population genetic studies. Pediatric disease subjects as well as related individuals were excluded.
Exome Variant Server http://evs.gs.washington.edu/EVS	Database of variants found during exome sequencing of several large cohorts of individuals of European and African American ancestry. Includes coverage data to inform the absence of variation.
1000 Genomes Project http://browser.1000genomes.org	Database of variants found during low-coverage and high-coverage genomic and targeted sequencing from 26 populations. Provides more diversity compared to the Exome Variant Server but also contains lower-quality data, and some cohorts contain related individuals.
dbSNP http://www.ncbi.nlm.nih.gov/snp	Database of short genetic variations (typically ≤ 50 bp) submitted from many sources. May lack details of the originating study and may contain pathogenic variants.
dbVar http://www.ncbi.nlm.nih.gov/dbvar	Database of structural variation (typically > 50 bp) submitted from many sources.
Disease databases	
ClinVar http://www.ncbi.nlm.nih.gov/clinvar	Database of assertions about the clinical significance and phenotype relationship of human variations.
OMIM http://www.omim.org	Database of human genes and genetic conditions that also contains a representative sampling of disease-associated genetic variants.
Human Gene Mutation Database http://www.hgmd.org	Database of variant annotations published in the literature. Requires fee-based subscription to access much of the content.
Locus/disease/ethnic/other-specific databases	
Human Genome Variation Society http://www.hgvs.org/dblist/dblist.html	The Human Genome Variation Society site developed a list of thousands of databases that provide variant annotations on specific subsets of human variation. A large percentage of databases are built in the Leiden Open Variation Database system.
Leiden Open Variation Database http://www.lovd.nl	
DECIPHER http://decipher.sanger.ac.uk	A molecular cytogenetic database for clinicians and researchers linking genomic microarray data with phenotype using the Ensembl genome browser.
Sequence databases	
NCBI Genome http://www.ncbi.nlm.nih.gov/genome	Source of full human genome reference sequences.
RefSeqGene http://www.ncbi.nlm.nih.gov/refseq/rsg	Medically relevant gene reference sequence resource.
Locus Reference Genomic (LRG) http://www.lrg-sequence.org	
MitoMap http://www.mitomap.org/MITOMAP/ HumanMitoSeq	Revised Cambridge reference sequence for human mitochondrial DNA.

In Silico Prediction tools

Table 2 In silico predictive algorithms


Category	Name	Website	Basis
Missense prediction	ConSurf	http://consurf.tau.ac.il	Evolutionary conservation
	FATHMM	http://fathmm.biocompute.org.uk	Evolutionary conservation
	MutationAssessor	http://mutationassessor.org	Evolutionary conservation
	PANTHER	http://www.pantherdb.org/tools/cnpScoreForm.jsp	Evolutionary conservation
	PhD-SNP	http://snps.biofold.org/phd-snp/phd-snp.html	Evolutionary conservation
	SIFT	http://sift.jcvi.org	Evolutionary conservation
	SNPs&GO	http://snps-and-go.biocomp.unibo.it/snps-and-go	Protein structure/function
	Align GVGd	http://agvgd.iarc.fr/agvgd_input.php	Protein structure/function and evolutionary conservation
	MAPP	http://mendl.stanford.edu/SidowLab/downloads/MAPP/index.html	Protein structure/function and evolutionary conservation
	MutationTaster	http://www.mutationtaster.org	Protein structure/function and evolutionary conservation
	MutPred	http://mutpred.mutdb.org	Protein structure/function and evolutionary conservation
	PolyPhen-2	http://genetics.bwh.harvard.edu/pph2	Protein structure/function and evolutionary conservation
	PROVEAN	http://provean.jcvi.org/index.php	Alignment and measurement of similarity between variant sequence and protein sequence homolog
	nsSNPAnalyzer	http://snpanalyzer.uthsc.edu	Multiple sequence alignment and protein structure analysis
Condel	http://bg.upf.edu/fannsdb/	Combines SIFT, PolyPhen-2, and MutationAssessor	
CADD	http://cadd.gs.washington.edu	Contrasts annotations of fixed/nearly fixed derived alleles in humans with simulated variants	
Splice site prediction	GeneSplicer	http://www.cbcb.umd.edu/software/GeneSplicer/gene_spl.shtml	Markov models
	Human Splicing Finder	http://www.umd.be/HSF/	Position-dependent logic
	MaxEntScan	http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoresq.html	Maximum entropy principle
	NetGene2	http://www.cbs.dtu.dk/services/NetGene2	Neural networks
	NNSplice	http://www.fruitfly.org/seq_tools/splice.html	Neural networks
FSPLICE	http://www.softberry.com/berry.phtml?topic=fsplce&group=programs&subgroup=gflnd	Species-specific predictor for splice sites based on weight matrices model	
Nucleotide conservation prediction	GERP	http://mendl.stanford.edu/sidowlab/downloads/gerp/index.html	Genomic evolutionary rate profiling
	PhastCons	http://compgen.bscb.cornell.edu/phast/	Conservation scoring and identification of conserved elements
	PhyloP	http://compgen.bscb.cornell.edu/phast/	Alignment and phylogenetic trees: Computation of <i>P</i> values for conservation or acceleration, either lineage-specific or across all branches

In silico tools/software prediction programs used for sequence variant interpretation.

Example GNOMAD View: CFTR



Example Gnomad View: DEAF1




Example Case:M2922

Clinical Features	Previous Genetic Testing	Exome <i>de novo</i> variants (filtering CADD > 20, ExAC freq < 0.001)
<ul style="list-style-type: none"> ▪ DD/ID ▪ Obesity ▪ Uplanting palpebral fissures ▪ Epicanthal folds ▪ Broad nasal bridge ▪ Micrognathia ▪ Hypotonia ▪ Sleep concerns ▪ Sleep disordered breathing ▪ Behavioral issues ▪ Volatile mood ▪ Sensory issues 	<ul style="list-style-type: none"> ▪ Normal chromosomal microarray ▪ Normal methylation studies ▪ Negative FISH for VCF and SMS ▪ Research analysis: <ul style="list-style-type: none"> ○ RAI1 sequence normal 	<p>Gene: <i>NDN</i> c.838G>C:p.A280P (ex 1) Variant: chr15:23931527 C>G Type: Missense CADD Phred: 25.8 Exac Frequency: 0</p> <p>Comment: <i>NDN</i> is hemizygous in PWS, imprinted gene, mono-allelic variant expression</p> <p>Gene: <i>MAPK8IP3</i> c.1364A>G:p.E455G (ex 11) Variant: chr16:1810461 A>G Type: Missense CADD Phred: 28.4 ExAC Frequency: 0</p> <p>Comment: Not reported in human disease</p>

***NDN* (necdin-like protein)**

- **One of 7 genes deleted in the Prader-Willi Syndrome contiguous gene deletion syndrome (15q11.2)**
 - PWS is characterized by hypogonadism, hypotonia, cognitive disability, behavior problems, and hyperphagia
- ***NDN* is an imprinted gene**
 - Only paternal allele is expressed
- Not previously described in monogenic human disease but relatively **constrained per ExAC**
- Identified variant (A280P) results in and Alanine to Proline change in a predicted **alpha helix of the protein structure**
 - Likely to disrupt protein secondary structure

Phasing the Variant




Nearby maternal SNP allows phasing of de novo variant to paternally inherited chromosome

Berger SI, et al. Human Genetics. 2017 Apr;136(4):409-420.

NDN Sanger Validation (variant on paternal allele)

de novo missense
c.838G>C

Maternal
inherited
silent SNP
c.858C>T



NDN Discussion

- **First de novo missense variant in this PWS region gene**
- **Our patient's phenotype may help explain:**
 - Contribution of NDN deficiency to the PWS cognitive phenotype
 - Respiratory features in NDN knockout mouse
 - Exclude contribution of deficient NDN to other PWS phenotypic features
- **Novel c.838G>C:p.A280P missense variant requires further functional evaluation to effects on NDN gene/protein function**
- **Can not exclude role of MAPK8IP3 variant**
 - (May also interact with NDN... Possible digenic effect)

Then this happened... MAPK8IP3

Ann Neurol. 2019 Jun;85(6):927-933. doi: 10.1002/ana.25481. Epub 2019 Apr 25.

Recurrent de novo MAPK8IP3 variants cause neurological phenotypes.

Iwasawa S¹, Yanagi K², Kikuchi A¹, Kobayashi Y^{3,4}, Haginoya K^{4,5}, Matsumoto H⁶, Kurosawa K⁷, Ochiai M⁸, Sakai Y⁸, Fujita A⁹, Miyake N⁹, Niihori T¹⁰, Shirota M¹¹, Funayama R¹², Nonoyama S⁶, Ohga S⁸, Kawame H¹³, Nakayama K¹², Aoki Y¹⁰, Matsumoto N⁹, Kaname T², Matsubara Y², Shoji W¹⁴, Kure S^{1,13}.

Summary

- Next generation sequencing pipelines can be tailored for germline variation, mosaic variation, small variants (SNV, indels), Copy number variants, etc.
- Clinical variant interpretation Guidelines
- Secondary findings

Thank you

- Children's Research Institute Computational Biology Unit
 - Dr. Eric Vilain - Director of Center for Genetic Medicine Research
 - Dr. Hiroki Morizono - Director of CBU
 - Dr. Susan Knoblach
 - Payal Banerjee
 - Dr. Surajit Bhattacharya
 - Dr. Hayk Barseghyan